Jennifer L Miller, MD - Research

Research at a glance

Top areas of exploration

Prader-Willi Syndrome , 48 publications
Hyperphagia , 8 publications
Chromosomes, Human, Pair 15 , 8 publications
Obesity , 7 publications

Research activity

68 publications

3,045 citations

Focus

My research focuses on investigation of the etiology and possible treatment for obesity and metabolic abnormalities in individuals with Prader-Willi syndrome and early-onset obesity. I have been working towards achieving an appropriate treatment for hyperphagia for the past 12 years. I currently follow over 500 patients with Prader-Willi syndrome from around the world, and over 100 patients with early-onset obesity due to other genetic causes. I am working on clinical treatment trials to treat hyperphagia in individuals with Prader-Willi syndrome and early-onset obesity..

Active clinical trials

RM-493-042

This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients 鈮�2 years of age who have completed or transitioned from a previous study with鈥�

Investigator: Jennifer L Miller
Status: Accepting Candidates
Ages: 2 Years - N/A
Sexes: All

RM-493-040

Investigator: Jennifer L Miller
Status: Accepting Candidates

C614

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.

Investigator: Jennifer L Miller
Status: Accepting Candidates
Ages: 4 Years - N/A
Sexes: All

My publications

68 publications

2023

Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.

The Journal of clinical endocrinology and metabolism

鈥�

2023

The Arduous Path to Drug Approval for the Management of Prader-Willi Syndrome: A Historical Perspective and Call to Action.

International journal of molecular sciences

鈥�

2022

Critical review of bariatric surgical outcomes in patients with Prader-Willi syndrome and other hyperphagic disorders.

Obesity (Silver Spring, Md.)

鈥�

2022

Molecular Classes and Growth Hormone Treatment Effects on Behavior and Emotion in Patients with Prader-Willi Syndrome.

Journal of clinical medicine

鈥�

2022

The Efficacy, Safety, and Pharmacology of a Ghrelin O-Acyltransferase Inhibitor for the Treatment of Prader-Willi Syndrome.

The Journal of clinical endocrinology and metabolism

鈥�

BOB体育